Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation  Giulia Renda, MD, PhD, Marco.

Similar presentations


Presentation on theme: "Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation  Giulia Renda, MD, PhD, Marco."— Presentation transcript:

1 Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation  Giulia Renda, MD, PhD, Marco Zimarino, MD, PhD, Fabrizio Ricci, MD, Jonathan P. Piccini, MD, Michael D. Ezekowitz, MD, PhD, Manesh R. Patel, MD, PhD, Riccardo Cappato, MD, Robert P. Giugliano, MD, Raffaele De Caterina, MD, PhD  The American Journal of Medicine  Volume 129, Issue 10, Pages e2 (October 2016) DOI: /j.amjmed Copyright © 2016 Elsevier Inc. Terms and Conditions

2 Figure 1 Flow chart showing the process of study selection. RCTs = randomized, controlled trials. The American Journal of Medicine  , e2DOI: ( /j.amjmed ) Copyright © 2016 Elsevier Inc. Terms and Conditions

3 Figure 2 Outcome comparison between non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in patients with atrial fibrillation undergoing cardioversion. Forest plot with individual and summary estimates of the risk ratio and 95% confidence interval (CI) of stroke/systemic embolism. A random-effects model was applied to estimate risk ratio and 95% CI. Squares and diamond sizes are proportional to study weight. The American Journal of Medicine  , e2DOI: ( /j.amjmed ) Copyright © 2016 Elsevier Inc. Terms and Conditions

4 Figure 3 Outcome comparison between non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in patients with atrial fibrillation undergoing cardioversion. Forest plot with individual and summary estimates of the risk ratio and 95% confidence interval (CI) of major bleeding. A random-effect model was applied to estimate risk ratio and 95% CI. Squares and diamond sizes are proportional to study weight. The American Journal of Medicine  , e2DOI: ( /j.amjmed ) Copyright © 2016 Elsevier Inc. Terms and Conditions

5 Supplementary Figure 1 Assessment of publication bias. Begg's funnel plot of studies according to the risk ratio (RR) of stroke/systemic embolism (A) and major bleeding (B) vs the standard error of risk ratio. The American Journal of Medicine  , e2DOI: ( /j.amjmed ) Copyright © 2016 Elsevier Inc. Terms and Conditions

6 Supplementary Figure 2 Jackknife sensitivity analysis. To evaluate whether the summary estimate of the effect could have been significantly affected by a single study, pooled estimates for stroke/systemic embolism (A) and major bleeding (B) were recalculated, using a random-effects model, by omitting one study at a time. Each line represents a reanalysis of the data with exclusion of one study at a time to assess the influence of this particular study on the overall result. The American Journal of Medicine  , e2DOI: ( /j.amjmed ) Copyright © 2016 Elsevier Inc. Terms and Conditions


Download ppt "Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation  Giulia Renda, MD, PhD, Marco."

Similar presentations


Ads by Google